Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

[摘要] BackgroundStandard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported.

[学科分类] 肿瘤学

[关键词] locally advanced NSCLC;survival;immunotherapy;PD-L1 expression;chemoradiotherapy